PT-141 (Bremelanotide): How This Peptide Works for Sexual Dysfunction

PT-141 (Bremelanotide): How This Peptide Works for Sexual Dysfunction

PT-141, also known by its pharmaceutical name bremelanotide (brand name Vyleesi), is the only peptide-based treatment for sexual dysfunction that has earned FDA approval. Unlike Viagra, Cialis, and other PDE5 inhibitors that work on blood flow, PT-141 works through the central nervous system, activating melanocortin receptors in the brain that influence sexual arousal and desire.

This distinction matters. Most sexual dysfunction treatments address the mechanical aspects of sexual function (erection quality, genital blood flow). PT-141 addresses the motivational component: the desire, arousal, and drive that precede the physical response. That makes it a fundamentally different tool, and one that fills a gap that other treatments cannot.

What Is PT-141 and Where Did It Come From?

PT-141’s origin story is one of medicine’s more interesting accidents. Researchers were studying Melanotan II, a synthetic peptide originally developed as a sunless tanning agent. Melanotan II activates melanocortin receptors, which stimulate melanin production in the skin (hence the tanning effect). During clinical trials, male participants reported an unexpected side effect: spontaneous erections.¹

This led researchers to investigate the sexual arousal effects more specifically. They modified Melanotan II to create PT-141 (bremelanotide), a cyclic peptide that retained the sexual arousal properties while reducing some of the other melanocortin effects. PT-141 specifically targets the melanocortin-4 receptor (MC4R), which is concentrated in brain areas involved in sexual arousal, motivation, and reward.²

After years of clinical development, the FDA approved bremelanotide in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This made it the first (and currently only) on-demand treatment for low sexual desire.

How PT-141 Works: The Melanocortin Pathway

To understand why PT-141 is different from every other sexual dysfunction treatment, you need to understand where it acts.

PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) work peripherally. They block the enzyme phosphodiesterase-5 in blood vessel walls, allowing nitric oxide to keep blood vessels dilated longer. The result is improved blood flow to the genitals. They do not affect desire, arousal, or motivation. They facilitate the mechanical response when the mental component is already present.³

PT-141 works centrally, in the brain. It activates melanocortin-4 receptors in the hypothalamus and limbic system, brain regions that process sexual arousal, desire, motivation, and reward. When MC4R is activated, it triggers downstream signaling through dopamine and oxytocin pathways that enhance:

• Sexual desire: the motivational drive to seek sexual activity
• Arousal: the physiological and psychological state of sexual readiness
• Genital response: increased genital sensitivity and blood flow (as a downstream effect of central arousal)

This central mechanism is why PT-141 can help patients for whom PDE5 inhibitors are insufficient. If the core issue is low desire rather than impaired blood flow, a blood-flow drug will not solve the problem. PT-141 addresses the upstream signal.

FDA Approval: What the Clinical Trials Showed

The FDA approval of Vyleesi was based on two phase III clinical trials (RECONNECT studies) enrolling approximately 1,247 premenopausal women with HSDD. HSDD is defined as persistently low sexual desire that causes personal distress, not explained by a medical condition, medication, or relationship issue.⁴

Results from the RECONNECT trials:

• Approximately 25% of PT-141-treated women experienced a meaningful increase in sexual desire (compared to 17% on placebo)
• Approximately 35% of PT-141-treated women experienced a meaningful decrease in distress related to low desire (compared to 31% on placebo)
• The treatment effect was statistically significant but modest in absolute terms
• Responders reported the effects as genuinely meaningful to their quality of life

The numbers deserve honest context. The response rates are not dramatic. But for women who do respond, PT-141 filled a void that no other medication could address. Before Vyleesi, the only FDA-approved drug for female HSDD was flibanserin (Addyi), which requires daily dosing and carries alcohol restrictions. PT-141 works on demand, taken only when desired, which many patients and clinicians consider a significant advantage.⁵

Off-Label Use in Men

While PT-141 is FDA-approved only for premenopausal women with HSDD, it is widely used off-label for male sexual dysfunction. The melanocortin receptor pathway is active in both sexes, and several studies have examined PT-141 in men.

Evidence in Male Erectile Dysfunction

Phase II trials of PT-141 in men with erectile dysfunction showed:

• Improved erectile function compared to placebo, measured by rigidity monitoring
• Effects that were independent of the PDE5 inhibitor pathway, meaning PT-141 worked even in some men who had not responded to Viagra or Cialis
• Particular benefit in men whose ED had a significant psychological or desire-related component
• The ability to produce erections without direct physical stimulation (unlike PDE5 inhibitors, which typically require sexual stimulation to work)

A pivotal study by Diamond et al. (2005) demonstrated that PT-141 produced erections in 67% of men with ED, including a subset of men who were non-responsive to sildenafil. The mechanism of action is complementary to PDE5 inhibitors, which is why some practitioners prescribe both together for treatment-resistant ED.⁶

Male Low Desire

Low testosterone is the most common hormonal cause of low libido in men, and testosterone replacement therapy (TRT) is the first-line treatment. But some men on adequate TRT still experience suboptimal desire. PT-141 can serve as an adjunct in these cases, addressing the central arousal pathway that testosterone alone may not fully activate.

Administration: How PT-141 Is Used

Subcutaneous Injection

The FDA-approved route for Vyleesi is subcutaneous injection. The standard dose is 1.75 mg injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The autoinjector makes self-administration straightforward.

Nasal Spray

Compounding pharmacies also prepare PT-141 as a nasal spray, which many patients prefer for convenience. Typical nasal spray doses range from 400 to 600 mcg per spray, with 1 to 2 sprays (total dose 400 to 1200 mcg) used 30 to 60 minutes before activity. Absorption through nasal mucosa is rapid, and some users report faster onset compared to subcutaneous injection.

Side Effects and Safety

The side effect profile of PT-141 is well-characterized from clinical trials and post-market use.

Common Side Effects

• Nausea: The most significant side effect, affecting approximately 40% of users in clinical trials. Usually mild to moderate, peaks about 2 hours after injection, and typically improves with repeated use. Taking an anti-nausea medication (ondansetron/Zofran) 30 minutes before PT-141 can help manage this.
• Flushing: Temporary facial and body flushing, similar to niacin flush. Occurs in about 20% of users.
• Headache: Reported in approximately 10 to 15% of users.
• Injection site reactions: Mild redness or irritation at the injection site. More common with repeated injections in the same area.

Cardiovascular Considerations

Other Safety Notes

• Skin darkening: Because PT-141 retains some melanocortin-1 receptor activity (the tanning receptor), some users notice mild darkening of existing moles or freckles with repeated use. This is typically reversible after discontinuation but should be monitored.
• Tolerance: Some users report diminished response with frequent use, which is one reason for the recommended frequency limits. Periodic breaks may help maintain efficacy.
• Drug interactions: No major drug interactions have been identified, but PT-141 should not be combined with other melanocortin receptor agonists. Use caution when combining with medications that affect blood pressure.

Cost and Access

Vyleesi (brand-name bremelanotide) carries a list price of approximately $850 to $1,000 per month (for 8 autoinjector doses). Insurance coverage varies significantly; some plans cover it for HSDD with prior authorization, while many do not.

Compounded PT-141 (available through compounding pharmacies with a prescription) is considerably less expensive, typically $100 to $300 per month depending on the form (injectable vial vs. nasal spray) and the pharmacy. Many functional and integrative medicine practitioners prescribe compounded PT-141, particularly for male patients (since Vyleesi is approved only for women).

Who Is PT-141 Best Suited For?

PT-141 is not a universal solution for sexual dysfunction. It works best for specific clinical profiles:

• Women with HSDD: The FDA-approved indication. Best candidates are premenopausal women with persistently low desire that causes distress, not explained by other medical conditions, medications, or relationship factors.
• Men with desire-related ED: Men whose erectile dysfunction has a significant psychological or low-desire component, particularly those who have not fully responded to PDE5 inhibitors alone.
• Combined with PDE5 inhibitors: For men with treatment-resistant ED, PT-141 plus a PDE5 inhibitor addresses both the central (desire/arousal) and peripheral (blood flow) components simultaneously.
• SSRI-related sexual dysfunction: Antidepressants commonly suppress sexual desire. PT-141 can partially counteract this by stimulating arousal through a separate pathway.

PT-141 is less likely to help when sexual dysfunction is purely mechanical (severe vascular ED without a desire component) or driven by relationship conflict, severe hormonal deficiency (where hormone replacement should come first), or untreated depression.

Related Reading

• Peptide Therapy: The Complete Guide
• Erectile Dysfunction: The Evidence-Based Guide
• ED Treatment Comparison: Medications, Devices, and Regenerative Options
• Low Libido in Women: Causes, Testing, and Treatment Options

References

1. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62904-0
2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
3. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114-128. doi:10.1016/j.mayocp.2016.09.018
4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
5. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. doi:10.2217/whe-2016-0018
6. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2006;18(1):58-63. doi:10.1038/sj.ijir.3901371